Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2016. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility (PDMR), or connected persons, specifically regarding the vesting of conditional share awards.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a specific corporate governance transaction and does not contain financial performance data.
Material Changes
The material event reported is the vesting of an award over American Depositary Shares (ADS) made in 2013 under the GlaxoSmithKline Share Value Plan (SVP). The restricted period for these awards ended, and the vesting occurred on February 28, 2016.
Outlook, Risks, and Unusual Items
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. The transaction was notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(c). The closing price of an ADS on February 26, 2015 (the business day prior to vesting), was US$39.14.
Key Facts for Investor Verification
- Transaction Type: Vesting of conditional share awards (ADS) under the 2013 Share Value Plan.
- Recipient: Dr K Slaoui, a connected person of Executive Director Dr M Slaoui.
- Quantity Vested: 2,990 ADS.
- Vesting Date: February 28, 2016.
- Reference Price: US$39.14 per ADS (closing price on February 26, 2015).